Navigation Links
Canada launches first gene therapy trial for Fabry disease
Date:1/24/2013

CALGARY Researchers in Calgary have launched the first gene therapy clinical trial in the world for Fabry disease, a rare inherited enzyme deficiency that can shorten the lifespan of people who have it by as much as 40 years.

Researchers will first remove a quantity of stem cells from a Fabry patient's blood. Then a working copy of a new gene will be inserted into the stem cells using a specially engineered virus. During the final phase of the trial, researchers hope to transplant these stem cells back into the donor patient and the new, working copy of the gene will make the missing enzyme.

The clinical trial has been prompted by promising gene therapy results in mice performed in the laboratory of Dr. Jeffrey Medin at the University Health Network in Toronto. Dr. Medin is the principal investigator of the pan-Canada team grant that is supporting this trial.

"We hope this will one day become a form of treatment that effectively cures Fabry disease," says Dr. Aneal Khan, a medical geneticist based at Alberta Children's Hospital, who is leading the Calgary segment of the national project.

"It could also help establish a platform on which we can create gene therapies for other illnesses and establish Calgary as a national leader in this experimental field of interventional genetics."

Although several gene therapies have been used in Canada for cancer, this study will be the first in the country to test a gene therapy for an inherited metabolic disorder.

People with Fabry disease have a change in a gene called GLA and can't make enough enzyme to break down a fatty substance called Gb3. The build-up of Gb3 can lead to problems in the kidneys, heart and brain. About 400 Canadians, including 25 Calgarians, have Fabry disease.

Although the project is headquartered in Toronto, physicians and scientists in Calgary will play a major role in the clinical trial. In particular, the lab at Foothills Medical Centre in Calgary has specialized expertise in the stem cell filtering process that will be used for the clinical trial.

"The trigger that's making all this possible is Calgary's expertise in isolating the specific blood stem cells we need," says Dr. Medin. "Without a sufficient quantity of those stem cells to work with, our likelihood of success would be greatly reduced."

In the Fabry trial, technologists led by Dr. Nicole Prokopishyn, director of the Calgary Laboratory Services Cellular Therapy Lab, processed the blood from a donor patient and isolated a specific type of stem cell called a CD34+ cell.

Christopher Armstrong, a 34-year-old Calgarian with Fabry disease, recently donated his blood for key initial experiments for the first phase of the trial. Nearly a billion of Christopher's CD34+ cells have been isolated and will be sent to Dr. Medin's lab in Toronto. Dr. Medin's team will take those cells and, using a modified virus, insert a working copy of the GLA gene into the stem cells.

"We use a type of virus called a lentivirus, which has been modified in a couple of critical ways," says Dr. Medin, who is also a professor in the Department of Medical Biophysics at the University of Toronto. "First, it's been stripped of any of its disease-causing capability and is safe. Second, it has the corrected functional GLA gene, which will cause the donor cells to make the correct enzyme. When the corrected cells circulate in the blood, they also secrete the enzyme, which is then taken up by unmodified cells. This effectively extends the therapy afforded by the modified stem cells."

The corrected cells go back into the donor patient, meaning there is less likelihood for rejection compared to cells coming from a different individual.

Like many other Fabry patients, Armstrong is currently on Enzyme Replacement Therapy (ERT), which requires a home care nurse to come to his house every two weeks to administer an infusion of medication. Although the infusions help manage his illness, they aren't a cure and they're something he has to organize his life around.

Armstrong, who was diagnosed in 2007, has experienced a thickening in one of the walls of his heart due to Fabry disease. "Even if the research meant that I had to come in once every six months for Enzyme Replacement Therapy, instead of every two weeks, then it would still be another step toward living a normal life," Armstrong says.

In the current pre-clinical phase of the study, researchers hope to demonstrate Armstrong's corrected stem cells are able to provide a source of enzyme in a specially adapted mouse that has Fabry disease. After this is accomplished, the second phase will repeat the experiment using a new donor with all the checks and balances needed for a human trial. Once the pre-clinical experimental results have satisfied the regulatory requirements of Health Canada, the team aims to treat the first human Fabry disease patient, which they estimate will be within two years.


'/>"/>
Contact: Gregory Harris
gregory.harris@albertahealthservices.ca
403-619-3108
Alberta Health Services
Source:Eurekalert

Related biology news :

1. Disease-carrying colonizers on the move: Predicting the spread of ticks across Canada
2. Ducks Unlimited Canada and Canadian Light Source partnership to shed light on wetlands
3. Potent human toxins prevalent in Canadas freshwaters
4. Meet Xenoceratops: Canadas newest horned dinosaur
5. USAs ancient hurricane belt and the US-Canada equator
6. Inspired: Canada funds 68 bold, inventive ways to improve health, save lives in developing countries
7. LABS, Inc. Launches Suite of Next-Generation Test Offerings; Focuses on Expanding Complex Biologic Testing Portfolio in 2012
8. Elsevier launches new journal Algal Research
9. Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
10. Thomson Reuters Launches Life Sciences Partner Ecosystem to Drive Collaborative R&D Drug Processes
11. WanderID Launches Breakthrough ID Product for Children, Seniors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
Breaking Biology News(10 mins):
(Date:5/26/2016)... ISELIN, New Jersey and ... -- Indegene ( http://www.indegene.com ), a ... solutions to life science, pharmaceutical and healthcare organisations ... provider of innovative scientific support throughout the product ... alliance with the launch of IntraScience. ...
(Date:5/26/2016)... ... 26, 2016 , ... FireflySci has been manufacturing quartz and ... over the globe. Their cute firefly logo has been spreading to more and ... spectrophotometer calibration standards that never require recalibration. These revolutionary standards have changed ...
(Date:5/25/2016)... Bethesda, Md. (PRWEB) , ... May 25, 2016 ... ... a request for information (RFI) issued by the Office of the National Coordinator ... the patient experience, and determines if clinically relevant data were available when and ...
(Date:5/24/2016)... ... 2016 , ... Cell therapies for a range of serious ... at Worcester Polytechnic Institute (WPI) that yielded a newly patented method of converting ... novel method, developed by WPI faculty members Raymond Page, PhD, professor of practice ...
Breaking Biology Technology: